Neuroscience金沙手机app平台

金沙平台注册

金沙手机app平台

Our focus
What we're working on
Collaboration stories
Our pipeline
Our medicines
Resources
Latest news

金沙平台注册

With a rich heritage and a research and development focus on specific aspects of neurodegenerative diseases, analgesia and psychiatry, AstraZeneca continues to push the boundaries of science in neuroscience in collaboration with other innovative partners across industry and academia. A significant unmet medical need remains in the areas of cognitive disorders, chronic pain and other central nervous system disorders.

更多 than 450 million people worldwide are affected by mental, neurological or behavioural problems, and the number is steadily rising.

We are committed to developing novel therapies that advance the science of neurodegenerative diseases and have the potential to provide a positive impact on patients around the world.

金沙手机app平台

MEDI1814 is a monoclonal antibody currently in Phase I development as a potential disease-modifying treatment for Alzheimer’s disease (AD). MEDI1814 is the first antibody to selectively target amyloid-beta 42, a form of amyloid which is particularly associated with AD. The build-up of plaque in the brain containing the peptide amyloid-beta is one of the key characteristics of AD. Early trials have shown that MEDI1814 can reduce levels of this 更多 toxic form of amyloid-beta in Alzheimer’s disease patients.

AstraZeneca and Lily are co-developing MEDI1814 as part of the BACE alliance.

^{Image: Artistic rendering of BACE enzyme.}

Partnering with influential organisations to extend the reach of our science to 更多 patients and healthcare providers

金沙平台注册

Opioid-induced constipation is a condition caused by prescription opioid pain medicines. The AstraZeneca and Daiichi Sankyo partnership expands our efforts in the US in order to get MOVANTIK to the large number of patients suffering with opioid-induced constipation.

Our approach in Neuroscience looks to maximise revenue through externalisation and on-market products; advance the novel product pipeline with partnerships where appropriate; and preserve a company stake in the most promising assets.

Our pipeline金沙手机app平台

金沙平台注册

View Pipeline

We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations. Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.

Find your country site in the AZ Network

Diprivan金沙手机app平台

propofol

EMLA金沙手机app平台

EMLA

Movantik/Moventig 金沙手机app平台

naloxegol

Naropin金沙手机app平台

ropivacaine

Seroquel IR金沙手机app平台

quetiapine fumarate

Seroquel XR金沙手机app平台

quetiapine fumarate

Xylocaine金沙手机app平台

lidocaine

Zomig, Zomig Rapimelt, Zomig Nasal Spray, AscoTop, Zomigon 金沙手机app平台

zolmitriptan

金沙平台注册

We publish information about the registration and results of all new and ongoing clinical trials for all products in all phases on our dedicated website.